Schrodinger Inc (SDGR)

$20.32 +0.74 (3.75%)
Market Cap 1.50B
Revenue (ttm) 207.54M
Net Income (ttm) -187.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.16%
Debt to Equity Ratio 0.00
Volume 1,896,900
Avg Vol 1,253,144
Day's Range N/A - N/A
Shares Out 73.61M
Stochastic %K 96%
Beta 1.67
Analysts Strong Sell
Price Target $27.40

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through...

Industry: Health Information Services
Sector: Healthcare
Phone: 212 295 5800
Address:
1540 Broadway, 24th Floor, New York, United States
Black22Edge
Black22Edge Aug. 23 at 2:08 AM
$SDGR Interesting code
0 · Reply
MGeronimo
MGeronimo Aug. 21 at 3:08 PM
$SDGR IN AT 19.48 bounce off support
0 · Reply
CrescentTrader
CrescentTrader Aug. 20 at 7:34 PM
$SDGR #STEM is the REAL UNDERVALUE champ here. Real revenue, multi-trillion sector, has over 70% market share in the energy and a.i. space, back to back POSITIVE EBIDTA quarters and cash flow positive and gross margins significantly increasing. Not even 1 billion market cap and SaaS company!
0 · Reply
scott52
scott52 Aug. 18 at 3:00 PM
$SDGR Cut my position in half. I may double up again as they head into q4.
1 · Reply
JarvisFlow
JarvisFlow Aug. 18 at 1:50 PM
Morgan Stanley updates rating for Schrodinger ( $SDGR ) to Equal-Weight, target set at 28 → 19.
0 · Reply
shrwd
shrwd Aug. 18 at 3:09 AM
$SDGR
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Aug. 17 at 5:02 AM
keeping it real with $SDGR won't buy till H% drops like usual
0 · Reply
scott52
scott52 Aug. 16 at 10:26 PM
$SDGR They should buy these guys. https://www.pathai.com/about-us#teamMembers Back in March 2025, the European Medicines Agency (EMA) qualified AIM-NASH, the first AI tool designed to assist pathologists in assessing liver biopsies for MASH/NASH. This was a big deal. The FDA is behind. But it will ultimately follow suit. The FDA's draft guidance on biopsies can be found here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-including-tissue-biopsies-clinical-trials Ramy should be building the one-stop shop for all BioPharma AI needs instead of pissing away money chasing clinical trial pipedreams. Fire Ramy. Hire someone who gets it. This is an AI company. Act like one.
0 · Reply
inflect1on
inflect1on Aug. 15 at 4:55 PM
$SDGR watching
0 · Reply
madnessofcrowds
madnessofcrowds Aug. 15 at 11:59 AM
$SDGR these analysts have no idea what they’re doing but sure, sell the day AFTER the news hits because some overpaid trend follower says it’s only slight undervalued instead of massively overvalued.
1 · Reply
Latest News on SDGR
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 15, 2025, 4:30 PM EDT - 8 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Announces Discontinuation of SGR-2921 Program

Aug 14, 2025, 7:00 AM EDT - 9 days ago

Schrödinger Announces Discontinuation of SGR-2921 Program

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:20 PM EDT - 17 days ago

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Schrödinger Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 17 days ago

Schrödinger Reports Second Quarter 2025 Financial Results

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Jul 25, 2025, 8:30 AM EDT - 4 weeks ago

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Jul 18, 2025, 10:25 AM EDT - 5 weeks ago

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

Jul 17, 2025, 8:00 AM EDT - 5 weeks ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 27, 2025, 8:00 AM EDT - 2 months ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Jun 13, 2025, 1:02 PM EDT - 2 months ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 12, 2025, 7:00 AM EDT - 2 months ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Jun 6, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Jun 5, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Jun 4, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Jun 2, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 3 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 5:00 PM EDT - 3 months ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 29, 2025, 8:00 AM EDT - 3 months ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 3 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 27, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 26, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 3 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025, 12:00 PM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

Schrödinger to Present at Jefferies Global Healthcare Conference

May 22, 2025, 8:30 AM EDT - 3 months ago

Schrödinger to Present at Jefferies Global Healthcare Conference

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

May 20, 2025, 11:37 PM EDT - 3 months ago

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

Schrödinger Announces CFO Appointment

May 20, 2025, 6:30 AM EDT - 3 months ago

Schrödinger Announces CFO Appointment

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 14, 2025, 9:30 AM EDT - 3 months ago

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

May 7, 2025, 5:59 PM EDT - 3 months ago

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 3 months ago

Schrödinger Reports Strong First Quarter 2025 Financial Results

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:30 AM EDT - 3 months ago

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 4 months ago

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Apr 23, 2025, 8:30 AM EDT - 4 months ago

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Apr 14, 2025, 8:00 AM EDT - 4 months ago

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Apr 12, 2025, 10:26 AM EDT - 4 months ago

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Mar 10, 2025, 8:30 AM EDT - 5 months ago

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Schrödinger: Still Waiting On A Catalyst

Mar 2, 2025, 1:24 AM EST - 6 months ago

Schrödinger: Still Waiting On A Catalyst

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:27 PM EST - 6 months ago

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

Feb 26, 2025, 4:05 PM EST - 6 months ago

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

Schrödinger to Participate in Upcoming Investor Conferences

Feb 24, 2025, 8:30 AM EST - 6 months ago

Schrödinger to Participate in Upcoming Investor Conferences

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

Feb 12, 2025, 8:30 AM EST - 6 months ago

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Jan 13, 2025, 7:00 AM EST - 7 months ago

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Nov 18, 2024, 8:30 AM EST - 9 months ago

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:51 AM EST - 10 months ago

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Black22Edge
Black22Edge Aug. 23 at 2:08 AM
$SDGR Interesting code
0 · Reply
MGeronimo
MGeronimo Aug. 21 at 3:08 PM
$SDGR IN AT 19.48 bounce off support
0 · Reply
CrescentTrader
CrescentTrader Aug. 20 at 7:34 PM
$SDGR #STEM is the REAL UNDERVALUE champ here. Real revenue, multi-trillion sector, has over 70% market share in the energy and a.i. space, back to back POSITIVE EBIDTA quarters and cash flow positive and gross margins significantly increasing. Not even 1 billion market cap and SaaS company!
0 · Reply
scott52
scott52 Aug. 18 at 3:00 PM
$SDGR Cut my position in half. I may double up again as they head into q4.
1 · Reply
JarvisFlow
JarvisFlow Aug. 18 at 1:50 PM
Morgan Stanley updates rating for Schrodinger ( $SDGR ) to Equal-Weight, target set at 28 → 19.
0 · Reply
shrwd
shrwd Aug. 18 at 3:09 AM
$SDGR
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Aug. 17 at 5:02 AM
keeping it real with $SDGR won't buy till H% drops like usual
0 · Reply
scott52
scott52 Aug. 16 at 10:26 PM
$SDGR They should buy these guys. https://www.pathai.com/about-us#teamMembers Back in March 2025, the European Medicines Agency (EMA) qualified AIM-NASH, the first AI tool designed to assist pathologists in assessing liver biopsies for MASH/NASH. This was a big deal. The FDA is behind. But it will ultimately follow suit. The FDA's draft guidance on biopsies can be found here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-including-tissue-biopsies-clinical-trials Ramy should be building the one-stop shop for all BioPharma AI needs instead of pissing away money chasing clinical trial pipedreams. Fire Ramy. Hire someone who gets it. This is an AI company. Act like one.
0 · Reply
inflect1on
inflect1on Aug. 15 at 4:55 PM
$SDGR watching
0 · Reply
madnessofcrowds
madnessofcrowds Aug. 15 at 11:59 AM
$SDGR these analysts have no idea what they’re doing but sure, sell the day AFTER the news hits because some overpaid trend follower says it’s only slight undervalued instead of massively overvalued.
1 · Reply
anachartanalyst
anachartanalyst Aug. 15 at 11:01 AM
$SDGR https://anachart.com/wp-content/uploads/ana_temp/1755255683_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 11:00 AM
Citigroup updates rating for Schrodinger ( $SDGR ) to Neutral, target set at 35 → 20.
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 15 at 5:55 AM
Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern $SDGR https://stocktwits.com/news/equity/markets/schrodinger-downgraded-by-citi-after-ending-blood-cancer-drug-trial-tied-to-2-deaths-retail-voices-concern/chsPhmRRdf5
0 · Reply
Jasooon
Jasooon Aug. 15 at 2:12 AM
$SDGR
0 · Reply
googleismyson
googleismyson Aug. 15 at 1:33 AM
$SDGR damn.... only got 3000 shares at $17.. due to pre-market fear FML...
0 · Reply
luckydirb
luckydirb Aug. 15 at 12:24 AM
$SDGR has Mr. Ramy been fired yet?
0 · Reply
Estimize
Estimize Aug. 14 at 8:00 PM
Wall St is expecting -0.74 EPS for $SDGR Q3 [Reporting 11/12 AMC] http://www.estimize.com/intro/sdgr?chart=historical&metric_name=eps&utm_c
0 · Reply
Buckanator
Buckanator Aug. 14 at 6:30 PM
$SDGR So this followed the “buy the fear” perfectly or buy the bad news.
1 · Reply
GuntherB
GuntherB Aug. 14 at 3:57 PM
$SDGR Was too scared to load up the boat in pre market, damn
1 · Reply
shavitmi
shavitmi Aug. 14 at 3:46 PM
$SDGR green close? $TEM
0 · Reply
scott52
scott52 Aug. 14 at 3:16 PM
$SDGR As pathetic as this is--they chose these three candidates to launch their proprietary program and they clearly did not choose well--it's better to fail fast in biotech. They didn't even complete phase 1 so the expenses here were minimal (relative to taking it into phase 2 or beyond) and operating expenses, which they have already lowered by cutting 7% of the workforce, will decrease even more. Now if they could just get rid of Ramy and replace him with someone who makes good decisions maybe the stock would go up.
0 · Reply
The300
The300 Aug. 14 at 3:13 PM
$SDGR patient deaths are tragic. if all you are concerned about is a few bucks, get your head (and your heaet) examine.
1 · Reply